Luca Richeldi

Residual respiratory impairment after COVID-19 pneumonia

A. Gasbarrini, L. Richeldi, G. Sgalla, 2021, BMC Pulmonary Medicine.

A real-time integrated framework to support clinical decision making for covid-19 patients

Valerio De Stefano, J. Lenkowicz, A. Cambieri, 2022, Computer Methods and Programs in Biomedicine.

Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant

G. Sgalla, L. M. Porro, Luca Richeldi, 2023, Chest Disease Reports.

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

G. Sgalla, J. Simonetti, Luca Richeldi, 2023, Expert opinion on biological therapy.

Promising advances in treatments for the management of idiopathic pulmonary fibrosis

G. Sgalla, Carmelo Sofia, A. Comes, 2024, Expert opinion on pharmacotherapy.

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond

G. Sgalla, Carmelo Sofia, A. Comes, 2023, Expert opinion on emerging drugs.